# Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

> **NCT05832229** · PHASE2 · RECRUITING · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 256 (estimated)

## Conditions studied

- Cirrhosis
- Cirrhosis, Liver
- Cirrhosis Early
- Cirrhosis Due to Hepatitis B
- Cirrhosis Advanced
- Cirrhosis Infectious
- Cirrhosis Alcoholic
- Cirrhosis Due to Hepatitis C

## Interventions

- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT05832229
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-07
- **Primary completion:** 2029-08-31
- **Final completion:** 2029-08-31
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2026-01-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05832229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05832229, "Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05832229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*